InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, acute myocardial infarction and saphenous vein graft coronary intervention. It utilizes MicroNet stent platform technology to develop its products and offers solutions for various disease conditions such as stenting, embolic showers, restenosis and late stent thrombosis. The company markets its products through a network of distributors in Israel and Germany. InspireMD is headquartered in Tel Aviv, Israel.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company InspireMD Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- InspireMD Inc Company Overview
- InspireMD Inc Company Snapshot
- InspireMD Inc Pipeline Products and Ongoing Clinical Trials Overview
- InspireMD Inc - Pipeline Analysis Overview
- InspireMD Inc - Key Facts
- InspireMD Inc - Major Products and Services
- InspireMD Inc Pipeline Products by Development Stage
- InspireMD Inc Ongoing Clinical Trials by Trial Status
- InspireMD Inc Pipeline Products Overview
- CGuard Embolic Prevention System
- CGuard Embolic Prevention System Product Overview
- CGuard Embolic Prevention System Clinical Trial
- CGuard Prime
- CGuard Prime Product Overview
- CGuard Prime Clinical Trial
- MGuard Drug Eluting Stent
- MGuard Drug Eluting Stent Product Overview
- Next Gen CGuard - 5F
- Next Gen CGuard - 5F Product Overview
- Next Generation Delivery System
- Next Generation Delivery System Product Overview
- NGuard
- NGuard Product Overview
- PVGuard Peripheral
- PVGuard Peripheral Product Overview
- RGuard Renal
- RGuard Renal Product Overview
- SwitchGuard Neuroprotection System
- SwitchGuard Neuroprotection System Product Overview
- SwitchGuard Neuroprotection System Clinical Trial
- InspireMD Inc - Key Competitors
- InspireMD Inc - Key Employees
- InspireMD Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- InspireMD Inc, Recent Developments
- Dec 09, 2024: InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
- Oct 15, 2024: InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
- Oct 07, 2024: InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
- Sep 16, 2024: InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System
- Aug 05, 2024: InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
- May 28, 2024: Inspiremd Announces Presentation Of Positive One-year Follow-up Results From The C-guardians U.S. Investigational Device Exemption (Ide) Clinical Trial Of Cguard At Linc 2024
- Mar 26, 2024: InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
- Feb 28, 2024: InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update
- Feb 12, 2024: InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System
- Jan 31, 2024: InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- InspireMD Inc Pipeline Products and Ongoing Clinical Trials Overview
- InspireMD Inc Pipeline Products by Equipment Type
- InspireMD Inc Pipeline Products by Indication
- InspireMD Inc Ongoing Clinical Trials by Trial Status
- InspireMD Inc, Key Facts
- InspireMD Inc, Major Products and Services
- InspireMD Inc Number of Pipeline Products by Development Stage
- InspireMD Inc Pipeline Products Summary by Development Stage
- InspireMD Inc Ongoing Clinical Trials by Trial Status
- InspireMD Inc Ongoing Clinical Trials Summary
- CGuard Embolic Prevention System - Product Status
- CGuard Embolic Prevention System - Product Description
- CGuard Embolic Prevention System - Acute Stroke of Carotid Artery Bifurcation Origin Treated with Use of the Micronet-covered CGUARD Stent Under Transient Flow Reversal Linked with Thrombus Retrieval: SAFEGUARD-STROKE Study
- CGuard Embolic Prevention System - An Early Feasibility Study (EFS) Assessing the CGuard Embolic Prevention Carotid Stent to Treat Severe Carotid Stenosis or Occlusion
- CGuard Embolic Prevention System - Long-term Outcomes of MicroNet-covered Stent Routine Use for Stroke Prevention in Symptomatic and Increased-risk Asymptomatic Carotid Stenosis Patients Requiring Revascularization by Neurovascular Team Decision: PARADIGM-EXTEND
- CGuard Embolic Prevention System - OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the CGuard Stent in Patients with Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study
- CGuard Prime - Product Status
- CGuard Prime - Product Description
- CGuard Prime - A Multicenter, Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System (80cm) When Used in Conjunction With the FDA-cleared ENROUTE Transcarotid Neuroprotection System (NPS) in Patients at High Risk for Adverse Events from Carotid Endarterectomy Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization (TCAR) Approach
- CGuard Prime - An EFS to Evaluate the Safety and Preliminary Effectiveness of the CGuard Prime Carotid Stent Placement in the Procedure Setting of Acute Ischemic Stroke
- MGuard Drug Eluting Stent - Product Status
- MGuard Drug Eluting Stent - Product Description
- Next Gen CGuard - 5F - Product Status
- Next Gen CGuard - 5F - Product Description
- Next Generation Delivery System - Product Status
- Next Generation Delivery System - Product Description
- NGuard - Product Status
- NGuard - Product Description
- PVGuard Peripheral - Product Status
- PVGuard Peripheral - Product Description
- RGuard Renal - Product Status
- RGuard Renal - Product Description
- SwitchGuard Neuroprotection System - Product Status
- SwitchGuard Neuroprotection System - Product Description
- SwitchGuard Neuroprotection System - A Study to Evaluate the Efficacy of SwitchGuard Neuroprotection System in Transcarotid Artery Revascularization Procedures
- InspireMD Inc, Key Employees
- InspireMD Inc, Other Locations
- Glossary
- InspireMD Inc Pipeline Products by Equipment Type
- InspireMD Inc Pipeline Products by Development Stage
- InspireMD Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bioiasis AD
- InterCure Ltd
- Etropal Ad
